logo-loader
RNS
viewFutura Medical PLC

Futura Medical PLC - GM Statement

RNS Number : 1981A
Futura Medical PLC
17 January 2020
 

 

17 January 2020

Result of General Meeting, Issue of Equity, Admission and Total Voting Rights

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology and focused on sexual health and pain, announces that, at its General Meeting held earlier today, all resolutions were duly passed by the shareholders.

Application has been made to the London Stock Exchange for 40,625,000 Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will be effective and trading will commence at 8.00 a.m. on 20 January 2020.

Following Admission, the Company will have 245,285,267 Ordinary Shares in issue. As the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 245,285,267 and this figure may therefore be used by Shareholders. 

Terms in this announcement have the meaning given to them in the Circular issued in connection with the Fundraising and the announcement released on 20 December 2019 with the RNS Number 7183X. 

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [email protected]
Tel: +44 (0) 1483 685 670
www.Futuramedical.com

 

Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [email protected]

Tel: +44 (0) 203 950 9144

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
GMSBRMTTMTBBBMM

Quick facts: Futura Medical PLC

Price: 9.25

Market: AIM
Market Cap: £22.72 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18